-
The Oliver Gatty PhD Studentship for full-time study and research training in the fields of Biophysical and Colloid Science is open to graduates in the broad area of biophysics. The Studentship is
-
analysis. Establishing whether ECM ageing can be rescued by UPR activation in human cells, using pharmacological UPR manipulation coupled with mass spectrometry, transcriptomics, and cutting edge biophysical
-
background in physics, biophysics, biological physics, or bioengineering. This PhD project will primarily focus on experimental research, which will include data analysis and there is scope for modelling
-
This PhD project explores the use of plasmonic nanostructures for trapping and spectroscopic characterization of proteins, enabling real-time, label-free studies of their structure, dynamics, and
-
Application deadline: 06/01/2026 Research theme: Biological Chemistry This 4-year PhD studentship is open to Home (UK) applicants. The successful candidate will receive an annual tax-free stipend
-
, analytical chemistry and enzymology. Working in an enthusiastic and supportive team the student will become expert in state-of-the-art (bio)chemistry, biophysics and photocatalysis. They will also expand
-
Application deadline: 28/11/2025 Research theme: Soft Matter and Biophysics How to apply: https://uom.link/pgr-apply-2425 This 3.5-year PhD is fully funded and open to applications from home
-
expression, purification and mutagenesis and liposome reconstitution, respirometic studies with isolated mitochondria), and biophysical methods to study protein dynamics, conformations and molecular
-
PhD Studentship: The Role of O-glycosylation of the Stalk Region of the Immunoglobulin Receptor GPVI
and experimental approaches: This project will utilise a range of cell-based and biophysical techniques. A list of the major techniques are provided below: Mammalian cell culture Site directed
-
, the race is on to understand how these DNA changes affect disease progression and post-operative recurrence risk. This PhD project uses CRISPR/Cas9 to examine risk variants in patient-derived cells and